Inhibikase Therapeutics gets dosing underway in – Seeking Alpha

Related Articles:

• The road ahead: 2021 January 25, 2021 # # # # At the start of each year, it is a useful practise to layout what is planned over the next 12 months. The events that are scheduled for the year to come, so that we can keep an eye out for them. Obviously, where 2021 will end actually is unpredictable, but an outline of what is scheduled…
• The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
• Monthly Research Review – January 2021 January 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during the previous 4 weeks. The post is divided into eight parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical…
• Top Parkinson’s Experts Join Inhibikase Therapeutics Scientific Advisory Board March 11, 2019 To further support its quest to advance a new therapy for Parkinson’s disease and related disorders, Inhibikase Therapeutics has added three leading researchers to its Scientific Advisory Board (SAB). The pharmaceutical company is developing protein kinase inhibitors for the treatment of neurological infections and neurodegenerative diseases. Its pipeline includes prospective therapies developed from its proprietary Re-engineering Approach with Metabolism Preserved…
• Monthly research review – October 2019 October 31, 2019   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during October 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
• Monthly Research Review – November 2019 November 30, 2019   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during November 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
• Monthly Research Review – September 2019 September 30, 2019   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during September 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
• 2019: Year in review December 31, 2019   In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2019. Month-by-month we will briefly discuss some of the major pieces of research/announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies to any researchers who…
• Prevail lands on a Lilly pad December 15, 2020 # # # # 2020 has been a dreadful year for most of the world – burdened by the outbreak and consequences of COVID-19. Despite this, there has been a steady stream of biotech acquisitions related to Parkinson’s which have helped to keep morale high in the PD research community. In October alone, we saw the Portuguese pharmaceutical company Bial…
• Monthy research review – December 2019 December 30, 2019   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during December 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
• DNA repair: Alpha synuclein to the rescue September 10, 2019   For the last 21 years, the protein alpha synuclein has developed a reputation as public enemy #1 in the world of Parkinson’s. Tiny errors in the DNA that provides the instructions from making the alpha synuclein protein were found to be the first genetic risk factor for the condition, and then the protein itself was found to be present…
• Monthly research review: February 2020 February 29, 2020   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during February 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
• Monthly Research Review: Jaunary 2020 January 31, 2020   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during January 2020. The post is divided into seven parts based on the type of research: Basic biology, Disease mechanism, Clinical research, New clinical trials, Clinical trial news, Other news, and…
• Viva Las Vagus August 20, 2019   Increasing preclinical evidence is being presented that suggests the gastrointestinal system can play a role in models of Parkinson’s. In addition, there is mounting epidemiological data indicating that the gut can have some kind of influence in people with the condition. Recently, a new paper was published which explores the involvement of the vagus nerve. This is the bundle…
• Monthly Research Review – August 2019 August 31, 2019   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during August 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
• Differentiating PD from MSA February 20, 2020   There is a lot of clinical and biological similarities between the neurodegenerative conditions of Parkinson’s and multiple systems atrophy (or MSA). Recently, however, researchers have published a report suggesting that these two conditions may be differentiated from each other using a technique analysing protein in the cerebrospinal fluid – the liquid surrounding the brain, that can be accessed via…
• Probiotics: Food for worms? January 24, 2020     There is a lot of research currently being conducted that is exploring the relationship between the gastrointestinal system and Parkinson’s. A growing body of data suggests that the bacteria in our guts may be having an infuential role. Recently researchers at the University of Edinburgh in Scotland have published the results of a study in which they used…
• PARP-kinson’s goes chlorogenic December 20, 2020 # # # # For a long time it was been reported that coffee may be able to reduce the risk of developing Parkinson’s, but the mechansim by which this association could be occurring has remained elusive. Now researchers from South Korea have discovered a biological pathway that could help to explain the protective association. It involves a protein called…
• Inhibikase Therapeutics Expands its Scientific Advisory Board with the Appointment of Leading Experts in Parkinson's Disease - GlobeNewswire March 19, 2019 Inhibikase Therapeutics Expands its Scientific Advisory Board with the Appointment of Leading Experts in Parkinson's Disease  GlobeNewswireATLANTA and BOSTON, March 19, 2019 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc., a pharmaceutical company developing protein kinase inhibitors ...
• Inhibikase Therapeutics, Inc. - Proactive Investors USA & Canada May 2, 2019 Inhibikase Therapeutics, Inc.  Proactive Investors USA & CanadaInhibikase Therapeutics Inc President & CEO Milton Werner sat down with Proactive Investors at the ThinkEquity Conference in New York.
• Natural (born) killers January 28, 2020   Today’s post starts with more of a biology lesson than usual, but it is important to understand where in the grand scheme of things a certain type of blood cell sits. That type of blood cell has a really cool name: Natural killer cells. Recently researchers at the University of Georgia (USA) published a report suggesting that natural killer…
• Being ly-mphatic about drainage issues February 4, 2021 # # # # The lymphatic network is an important part of our body’s defense system. It is made up of an enormous web of vessels and nodes which help to protect us from infection and disease. This network transports a colourless fluid (called lymph), which serves two primary functions: 1.) it contains infection-fighting white blood cells that help in…